OraSure Defends Strategy Amid Activist Altai Governance Challenge

Orasure Technologies ( (OSUR) ) has issued an announcement.

On March 30, 2026, OraSure Technologies released a presentation defending its performance and governance in response to activist investor Altai Capital’s push to replace two independent directors, highlighting that its shareholder returns have matched or exceeded a selected diagnostics peer set during CEO Carrie Eglinton Manner’s tenure. The company emphasized a focused growth strategy built on stabilizing public health funding, new products such as Colli-Pee and the Sherlock CT/NG self-test, and a path to operating cash flow breakeven in 2026, arguing that Altai undervalues its M&A pipeline and that a sale process now would jeopardize value from pending FDA decisions and ongoing margin expansion.

OraSure detailed cost-cutting and operational restructuring since 2023, including site closures, workforce reductions of about 40%, and automation that has lifted gross margins and reduced SG&A, creating operating leverage as volumes recover. Management also pointed to disciplined capital allocation, a debt-free balance sheet with substantial cash, share repurchases at prices below Altai’s valuation range, and equity-heavy executive and director compensation as evidence of alignment with shareholders, while questioning Altai’s analysis and the track record of its principal, Rishi Bajaj.

The most recent analyst rating on (OSUR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.

Spark’s Take on OSUR Stock

According to Spark, TipRanks’ AI Analyst, OSUR is a Neutral.

The score is held back primarily by deteriorated financial performance (losses, sharp revenue contraction, and recent cash burn). The latest earnings call provides partial support via stabilization signals (improving gross margin outlook, strong cash/no debt, and product-catalyst pipeline), while technicals are neutral-to-slightly positive and valuation remains challenged due to negative earnings.

To see Spark’s full report on OSUR stock, click here.

More about Orasure Technologies

OraSure Technologies, Inc. is a diagnostics company focused on oral fluid and other specimen collection devices and in vitro diagnostic tests, serving public health, consumer and clinical testing markets in the U.S. and internationally. The company is leveraging its existing platforms and manufacturing capacity to expand in at-home and point-of-care testing, including sexually transmitted infection and urine-based diagnostics.

Average Trading Volume: 552,001

Technical Sentiment Signal: Sell

Current Market Cap: $207.4M

For detailed information about OSUR stock, go to TipRanks’ Stock Analysis page.